Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
about
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinomaPrediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
P2860
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@en
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@nl
type
label
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@en
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@nl
prefLabel
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@en
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
Advanced malignancies treated ...... e mTOR inhibitor temsirolimus.
@en
P2093
Bonnie S Glisson
David S Hong
Jennifer J Wheler
Merrill S Kies
Ralph G Zinner
Sarina A Piha-Paul
Susan Kambrick
Vivek Subbiah
Xiaochun Liu
P2860
P304
23227-23238
P356
10.18632/ONCOTARGET.7594
P407
P577
2016-02-24T00:00:00Z